KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Notes Payables (2016 - 2021)

Abbott Laboratories' Notes Payables history spans 13 years, with the latest figure at $197.0 million for Q3 2021.

  • On a quarterly basis, Notes Payables fell 5.29% to $197.0 million in Q3 2021 year-over-year; TTM through Sep 2021 was $197.0 million, a 5.29% decrease, with the full-year FY2020 number at $213.0 million, up 5.97% from a year prior.
  • Notes Payables hit $197.0 million in Q3 2021 for Abbott Laboratories, down from $199.0 million in the prior quarter.
  • Over the last five years, Notes Payables for ABT hit a ceiling of $341.0 million in Q2 2018 and a floor of $197.0 million in Q3 2021.
  • Historically, Notes Payables has averaged $213.6 million across 5 years, with a median of $205.0 million in 2020.
  • Biggest five-year swings in Notes Payables: plummeted 92.46% in 2017 and later surged 56.42% in 2018.
  • Tracing ABT's Notes Payables over 5 years: stood at $206.0 million in 2017, then dropped by 2.91% to $200.0 million in 2018, then rose by 0.5% to $201.0 million in 2019, then grew by 5.97% to $213.0 million in 2020, then fell by 7.51% to $197.0 million in 2021.
  • Business Quant data shows Notes Payables for ABT at $197.0 million in Q3 2021, $199.0 million in Q2 2021, and $199.0 million in Q1 2021.